ASH 2023 | An overview of trials investigating asciminib in the treatment of Ph+ CML

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of trials investigating asciminib, an allosteric inhibitor of BCR::ABL1, in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). He mentions the X2101 trial (NCT02081378), which found promising efficacy of asciminib monotherapy and in combination with ATP competitive tyrosine kinase inhibitors (imatinib, nilotinib, or dasatinib). The safety and efficacy outcomes from this trial were sustained during an 8-year follow-up. Dr Mauro also notes positive results from the ALLG CML13 ASCEND-CML trial, indicating the potential of asciminib therapy in the frontline treatment of CML. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.